Nutrient cocktail for early Alzheimer's passes second trial

September, 2012
  • A second controlled trial of the nutrient cocktail Souvenaid has confirmed its cognitive benefits for those in the early stages of Alzheimer’s.

Two years ago, I reported on a clinical trial of a nutrient cocktail called Souvenaid for those with early Alzheimer’s. The three-month trial, involving 225 patients, had some success in improving verbal recall, with those with the mildest level of impairment benefiting the most.

The ‘cocktail’, designed by a MIT professor of brain and cognitive science, includes choline, uridine and the omega-3 fatty acid DHA. Earlier research indicated that these nutrients — precursors to the lipid molecules that help make up neural membranes — need to be administered together to be effective. In animal studies, the cocktail increased the number of dendritic spines, which are reduced in Alzheimer’s disease.

A further trial of the supplement has now been reported on. This randomized, controlled double-blind study followed 259 patients with early Alzheimer’s for six months. The placebo group was given an iso-caloric control product. Compliance was high (around 97%), and no serious side effects occurred.

During the first three months, all patients improved their verbal memory performance, but after that those on placebo began to deteriorate, while those on Souvenaid continued to improve. Their performance at the end of the trial was significantly better than that of the placebo group. Moreover, brain scans showed that their brains began to show more normal activity patterns, consistent with the regaining of greater synaptic function.

Because the supplement only seems to be effective for those in the early stages (in this study, participants averaged around 25 on a scale of dementia that ranges from 1 to 30, with 30 being normal), a two-year trial is now underway with patients with MCI.

Reference: 

Scheltens, P. et al. 2012. Efficacy of Souvenaid in Mild Alzheimer’s Disease: Results from a Randomized, Controlled Trial. Journal of Alzheimer’s Disease, 31 (1), 225-36.

Related News

As we all know, people are living longer and obesity is at appalling levels. For both these (completely separate!) reasons, we expect to see growing rates of dementia. A new analysis using data from the long-running Framingham Heart Study offers some hope to individuals, however.

A study involving 39 older adults has found that those randomly assigned to a “high-challenge” group showed improved cognitive performance and more efficient brain activity compared with those assigned to a low-challenge group, or a control group.

Data from 2,800 participants (aged 65+) in the Advanced Cognitive Training for Independent and Vital Elderly (ACTIVE) study has revealed that one type of cognitive training benefits less-educated people more than it does the more-educated.

A study involving 266 people with mild cognitive impairment (aged 70+) has found that B vitamins are more effective in slowing cognitive decline when people have higher omega 3 levels.

Growing research has implicated infections as a factor in age-related cognitive decline, but these have been cross-sectional (comparing different individuals, who will have a number of other, possibly confounding, attributes).

Another study adds to the growing evidence that a Mediterranean diet is good for the aging brain.

A two-year study which involved metabolic testing of 50 people, suggests that Alzheimer's disease consists of three distinct subtypes, each one of which may need to be treated differently. The finding may help explain why it has been so hard to find effective treatments for the disease.

A study involving both mice and human cells adds to evidence that stress is a risk factor for Alzheimer's.

Data from 23,572 Americans from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study has revealed that those who survived a stroke went on to have significantly faster rates of cognitive decline as they aged.

A study involving 382 older adults (average age 75) followed for around five years, has found that those who don’t get enough vitamin D may experience cognitive decline at a much faster rate than people who have adequate vitamin D.

Pages

Subscribe to Latest newsSubscribe to Latest newsSubscribe to Latest health newsSubscribe to Latest news
Error | About memory

Error

The website encountered an unexpected error. Please try again later.